H. Hayashi

R. Kaiser, K. Azuma, I. Okamoto, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung

Kaoru Tanaka, K. Azuma, I. Okamoto, 2013, Cancer Chemotherapy and Pharmacology.

S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?

T. Mitsudomi, H. Hayashi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.

K. Nishio, J. Tanizaki, K. Nakagawa, 2016, Lung cancer.

Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

O. Nishiyama, Y. Tohda, J. Tanizaki, 2021, BMC Pulmonary Medicine.

Prognostic Impact of Minimal Pericardial Effusion in Patients With Advanced Non–small‐cell Lung Cancer

Kaoru Tanaka, K. Nakagawa, Y. Chiba, 2017, Clinical lung cancer.

Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.

Kaoru Tanaka, J. Tanizaki, K. Nakagawa, 2016, Lung cancer.

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

J. Watanabe, A. Ono, T. Takahashi, 2014, Cancer Chemotherapy and Pharmacology.

A Randomized Phase II Study Comparing Nivolumab With Carboplatin‐Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small‐Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Stud

T. Mitsudomi, C. Kitagawa, K. Nishio, 2017, Clinical lung cancer.

Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy

Hiromasa Yamamoto, T. Ohira, M. Tsuboi, 2021, Cancer science.

Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT)

M. Tsuboi, M. Okada, T. Mitsudomi, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.

T. Mitsudomi, K. Nishio, H. Hayashi, 2015, Anticancer research.

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

K. Nakagawa, H. Hayashi, 2013 .

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR

Y. Hasegawa, K. Nakagawa, M. Takeda, 2017, ESMO Open.

Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity

K. Nakagawa, M. Takeda, H. Hayashi, 2016, Investigational New Drugs.

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).

K. Nishio, S. Ikeda, K. Azuma, 2022, Lung cancer.

Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L.

Young Hak Kim, Y. Nishimura, Y. Hasegawa, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?

K. Nakagawa, H. Hayashi, Satomi Watanabe, 2016, Annals of translational medicine.

An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.

T. Mitsudomi, S. Tomida, M. D. De Velasco, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer

S. Cedrés, D. Planchard, K. Yoh, 2020, Investigational New Drugs.

Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study

N. Yamamoto, K. Nakagawa, H. Akamatsu, 2021, JTO clinical and research reports.

Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)

M. Satouchi, K. Azuma, I. Okamoto, 2021, Cancer management and research.

Melanoma Transition Is Frequently Accompanied by a Loss of Cytoglobin Expression in Melanocytes: A Novel Expression Site of Cytoglobin

M. D. De Velasco, K. Nishio, S. Koinuma, 2014, PloS one.

Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed

I. Okamoto, K. Kunimasa, K. Nakagawa, 2010, International Journal of Clinical Oncology.

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

J. Sakamoto, N. Masuda, T. Satoh, 2013, Breast Cancer.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer

K. Matsumoto, K. Nishio, I. Okamoto, 2013, Oncogene.

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2020, British Journal of Cancer.

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.

T. Yamanaka, M. Okada, A. Kubo, 2015 .

Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.

A. Shaw, S. Ou, Gregory Riely, 2018 .

The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC

S. Tomida, K. Nishio, Y. Fukuda, 2022, JTO clinical and research reports.

Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer.

Y. Nishimura, Kaoru Tanaka, T. Satoh, 2013, Anticancer research.

Phase 3 Clinical Trial for the Combination of Erlotinib plus Ramucirumab Compared with Osimertinib in Previously Untreated Advanced or Recurrent Non–Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)

M. Oki, K. Azuma, N. Yamamoto, 2021, Clinical Lung Cancer.

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

J. Tanizaki, K. Nakagawa, K. Yonesaka, 2019, Cancer medicine.

Progression from early to advanced stage of immune‐related cholangitis

M. Kudo, Y. Minami, S. Hagiwara, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC.

M. Kudo, I. Matsumura, T. Okuno, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1

J. Tanizaki, K. Nakagawa, Y. Chiba, 2016, Oncotarget.

Localized malignant pleural mesothelioma showing a thoracic mass and metastasizing to the stomach.

K. Notohara, T. Ishida, H. Yoshioka, 2010, Internal medicine.

Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection

M. Kudo, Y. Minami, S. Hagiwara, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.

B. Solomon, Dong-Wan Kim, Geoffrey Liu, 2022, Lung cancer.

Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2022, Lung cancer.

Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study.

T. Yamanaka, A. Kubo, K. Azuma, 2021, European journal of cancer.

Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.

Masato Terashima, Masatoshi Kudo, Masayuki Kitano, 2015, Cancer letters.

Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society

A. Gemma, Y. Ohe, K. Kiura, 2022, JTO clinical and research reports.

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study

B. Solomon, J. Jassem, Geoffrey Liu, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Severe Immune-Related Hepatitis Treated With Plasma Exchange.

M. Kudo, S. Hagiwara, K. Nakagawa, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.

Kaoru Tanaka, Y. Hasegawa, J. Tanizaki, 2020, The Oncologist.

Giant Tumor of Parotid Gland; A Case Report.

H. Hayashi, Y. Hamaguchi, M. Hattori, 1993 .

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.

E. Smit, Melissa L. Johnson, E. Felip, 2022, Journal of Clinical Oncology.

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Kaoru Tanaka, K. Nishio, A. Tsuya, 2021, Clinical Cancer Research.

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

Melissa L. Johnson, P. Janne, Dong-Wan Kim, 2021, Cancer discovery.

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

P. Jänne, Melissa L. Johnson, Dong-Wan Kim, 2021 .

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2

Kaoru Tanaka, K. Nishio, J. Tanizaki, 2018, Oncotarget.

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer

S. Tomida, Kaoru Tanaka, Y. Fukuda, 2020, Clinical Cancer Research.

Combination therapy with PD-1 or PD-L1 inhibitors for cancer

K. Nakagawa, H. Hayashi, 2019, International Journal of Clinical Oncology.

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

T. Mitsudomi, S. Tomida, Kaoru Tanaka, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.

A. Ardizzoni, C. Grohé, J. Gray, 2021, Clinical lung cancer.

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Yusuke Nakamura, T. Mitsudomi, M. D. De Velasco, 2017, BMC Cancer.

MEK inhibitors against MET-amplified non-small cell lung cancer

Yusuke Nakamura, T. Mitsudomi, S. Tomida, 2016, International journal of oncology.

Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2

Yusuke Nakamura, T. Mitsudomi, S. Tomida, 2016, Clinical Cancer Research.

MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.

T. Mitsudomi, S. Tomida, K. Nishio, 2015, Lung cancer.

Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study

Y. Nishimura, Kaoru Tanaka, K. Doi, 2020, Anti-cancer drugs.

Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.

S. Tomida, K. Nishio, Y. Iwamoto, 2020, JAMA oncology.

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.

H. Mukai, Y. Ohashi, K. Nishio, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 5169: Novel target molecules for treatment of cancer of unknown primary

K. Nishio, K. Nakagawa, T. Kurata, 2018, Tumor Biology.

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.

S. Tomida, M. D. De Velasco, K. Nishio, 2015, Lung cancer.

O3-15-2CHRONIC NICOTINE EXPOSURE MEDIATES RESISTANCE TO EGFR-TKI IN EGFR-MUTATED LUNG CANCER VIA EGFR SIGNAL

S. Tomida, K. Nishio, K. Okamoto, 2014 .

Clinicopathological and genetic differences between low‐grade and high‐grade colorectal mucinous adenocarcinomas

K. Okuno, S. Tomida, M. D. De Velasco, 2015, Cancer.

Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production

M. D. De Velasco, K. Nishio, H. Shiozaki, 2013, Oncotarget.

Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Keunchil Park, M. Fukuoka, K. Kiura, 2018, Cancer science.

ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer

M. Fukuoka, K. Kiura, M. Satouchi, 2018, Cancer science.

CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer

S. Akinaga, M. Satouchi, H. Murakami, 2013, British Journal of Cancer.

Open-Label Phase II Study of the Efficacy of Nivolumab for Cancer of Unknown Primary.

K. Yonemori, Y. Iwamoto, J. Tanizaki, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and immune profiling for cancer of unknown primary site

S. Tomida, K. Nishio, J. Tanizaki, 2019, Journal of Immunotherapy for Cancer.

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI

Kaoru Tanaka, K. Nishio, K. Doi, 2019, Oncogenesis.

Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.

M. Takeda, H. Hayashi, K. Nakagawa, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer

M. Kudo, M. Takenaka, Kaoru Tanaka, 2017, Investigational New Drugs.

[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification

K. Nakagawa, K. Yonesaka, M. Takeda, 2019, International journal of cancer.

Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.

K. Okuno, S. Tomida, M. D. De Velasco, 2015, International journal of oncology.

Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.

Y. Nishimura, K. Nishio, I. Okamoto, 2012, Anticancer research.

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Kaoru Tanaka, Y. Hasegawa, J. Tanizaki, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Kaoru Tanaka, K. Nishio, Y. Hasegawa, 2018, Clinical Cancer Research.

Diagnosis, treatment and prognosis of blowout fracture of the orbit.

Akihiko Kato, H. Hayashi, A. Yuta, 1990 .

Abstract. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are efficacious drugs for non‐small cell lung cancers (NSCLCs) with EGFR‐activating mutations. Afatinib, a second-generation EGFR-TKI and osimertinib, a third-generation EGFR-TKI, are both standard therapies for patien

T. Mitsudomi, K. Nakagawa, Y. Chiba, 2018 .

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Yusuke Nakamura, T. Mitsudomi, M. D. De Velasco, 2016, Cancer science.

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study

M. Satouchi, M. Nishio, Toshiaki Takahashi, 2020, Cancer science.

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition

K. Okuno, S. Tomida, M. D. De Velasco, 2014, International journal of oncology.

Abstract. Patients with non-small cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements

K. Okuno, S. Tomida, K. Nishio, 2014 .

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

S. Morita, K. Azuma, N. Yamamoto, 2021, JAMA oncology.

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.

S. Morita, K. Kunimasa, T. Ishida, 2011, Lung cancer.

Inhibition of &bgr;-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation

S. Tomida, M. D. De Velasco, K. Nishio, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Significance of FGF9 gene in resistance to anti‐EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti‐EGFR therapies

S. Tomida, M. D. De Velasco, K. Nishio, 2017, Molecular carcinogenesis.

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines

M. D. De Velasco, K. Nishio, K. Sakai, 2014, SpringerPlus.

Cell Lung Cancer Small − Positive Non − Resistance to ALK Inhibitors in EML 4-ALK Activation of HER Family Signaling as a Mechanism of Acquired

Kaoru Tanaka, K. Nishio, I. Okamoto, 2013 .

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC

Yusuke Nakamura, S. Tomida, M. D. De Velasco, 2016, Molecular Cancer Therapeutics.

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Kaoru Tanaka, K. Nishio, K. Azuma, 2019, Scientific Reports.

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration

Jeffrey W. Clark, A. Drilon, R. Heist, 2019, Nature Medicine.

KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

K. Nishio, J. Tanizaki, K. Nakagawa, 2021, Clinical Cancer Research.

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis

Haiyi Jiang, L. Paz-Ares, K. Azuma, 2021, International Journal of Clinical Oncology.

Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L).

Y. Kogure, Y. Nakanishi, T. Oguri, 2019, Japanese journal of clinical oncology.

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

K. Nishio, K. Azuma, Y. Fukuda, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

Y. Hosomi, Y. Ohe, K. Kubota, 2019, Investigational New Drugs.

Administration of gefitinib via nasogastric tube effectively improved the performance status of a patient with lung adenocarcinoma-derived meningeal carcinomatosis

A. Kato, T. Okuda, K. Nakagawa, 2014, International Cancer Conference Journal.

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma

K. Okuno, K. Nishio, H. Shiozaki, 2013, International journal of oncology.

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

K. Nishio, K. Nakagawa, H. Hayashi, 2014, Drug design, development and therapy.

Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2019, Lung cancer.

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer

Kaoru Tanaka, K. Azuma, K. Nakagawa, 2019, Thoracic cancer.

Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2019, Lung cancer.

Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial

T. Yamanaka, M. Okada, A. Kubo, 2016, Cancer.

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer

K. Nakagawa, T. Kurata, H. Hayashi, 2011, Clinical Medicine Insights. Oncology.

Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer

M. Kudo, S. Tomida, M. D. De Velasco, 2014, Molecular Cancer.

Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis

M. Kudo, K. Ueshima, T. Sakurai, 2021, Frontiers in Oncology.

Effect of niceritrol combined with other drugs in the treatment of facial palsy.

H. Hayashi, Takeshi Shimizu, Y. Sakakura, 1987 .

Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.

S. Morita, M. Taguri, I. Okamoto, 2013, Clinical lung cancer.

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)

M. Oki, H. Saka, K. Azuma, 2022, Journal for ImmunoTherapy of Cancer.

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Kaoru Tanaka, Y. Hasegawa, K. Nakagawa, 2017, JAMA oncology.

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?

K. Nakagawa, H. Hayashi, K. Haratani, 2020, BMC Medicine.

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer

K. Nishio, J. Tanizaki, K. Nakagawa, 2018, Cancer science.

Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer.

T. Mitsudomi, S. Tomida, K. Nishio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401)

M. Fukuoka, M. Satouchi, S. Kudoh, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I trial of OTS11101, an anti‐angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor

Kaoru Tanaka, K. Nishio, T. Satoh, 2013, Cancer science.

Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial

Kaoru Tanaka, K. Nishio, K. Sakai, 2021, Medical Oncology.

MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations

K. Okuno, S. Tomida, M. D. De Velasco, 2014, Molecular Cancer Therapeutics.

Cancer Biology and Signal Transduction MEK Inhibitor for Gastric Cancer with MEK 1 Gene Mutations

K. Okuno, S. Tomida, K. Nishio, 2014 .

A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood

K. Nishio, K. Nakagawa, S. Shimizu, 2020, Case Reports in Oncology.

Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab

Kaoru Tanaka, J. Tanizaki, K. Nakagawa, 2017, ESMO Open.

Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.

W. Ichikawa, R. Matoba, M. Fujii, 2023, European journal of cancer.

Cystic brain metastasis in non-small-cell lung cancer with ALK rearrangement.

Y. Nishimura, A. Kato, Kaoru Tanaka, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of myringotomy and orally administered. S-carboxymethylcysteine on viscoelasticity of middle ear effusions in children with otitis media with effusion.

K. Takeuchi, H. Hayashi, Y. Majima, 1987 .

Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Keunchil Park, Y. Ichinose, E. Cho, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma

K. Nishio, Ken Kato, T. Hamaguchi, 2014, Oncotarget.

Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study

K. Yonemori, K. Tamura, T. Koyama, 2022, Investigational New Drugs.

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer.

M. Taguri, I. Okamoto, K. Nakagawa, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Overexpression of heparan sulfate 6-O-sulfotransferase-2 in colorectal cancer

K. Okuno, M. D. De Velasco, K. Nishio, 2013, Molecular and clinical oncology.

Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer

K. Nakagawa, T. Kurata, Y. Fujisaka, 2014, Investigational New Drugs.

Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells

W. Nishio, C. Ohbayashi, M. D. De Velasco, 2013, Cancer medicine.

Slug is upregulated during wound healing and regulates cellular phenotypes in corneal epithelial cells.

K. Sugioka, K. Nishio, Y. Shimomura, 2012, Investigative ophthalmology & visual science.

[Drug-induced pulmonary damage due to inhalation of a waterproof spray].

T. Ishida, H. Yoshioka, H. Hayashi, 2008, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer.

Michael Thomas, E. Felip, S. Shreeve, 2021, Future Oncology.

Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: successful treatment of one case with rociletinib.

M. Takeda, H. Hayashi, H. Kaneda, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Hip Arthroscopic Osteochondral Autologous Transplantation for Treating Osteochondritis Dissecans of the Femoral Head.

Hajime Utsunomiya, H. Hayashi, A. Sakai, 2015, Arthroscopy techniques.

Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.

K. Nakagawa, K. Yonesaka, M. Takeda, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study.

K. Azuma, H. Kenmotsu, Toshiaki Takahashi, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib

Kaoru Tanaka, K. Nishio, J. Tanizaki, 2021, International Journal of Clinical Oncology.

Retrospective study of unplanned hospital admission for metastatic cancer patients visiting the emergency department

M. Taguri, K. Okamoto, H. Hayashi, 2017, Supportive Care in Cancer.

Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)

N. Yamamoto, R. Toyozawa, K. Nakagawa, 2020, Journal for ImmunoTherapy of Cancer.

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN

S. Oizumi, M. Nishio, S. Sugawara, 2023, JTO clinical and research reports.

760PRisk factors for febrile neutropenia (FN) in unresectable/recurrent pancreatic cancer(PC) patients(pts) receiving FOLFIRINOX (FFX) from JASPAC06 study

H. Ueno, Mitsuhito Sasaki, N. Mizuno, 2017 .

Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)

Kaoru Tanaka, K. Nishio, H. Matsuoka, 2022, The oncologist.

Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.

Kaoru Tanaka, K. Nishio, Y. Hasegawa, 2021, European journal of cancer.

Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial

M. Kusumoto, M. Ando, Y. Kondoh, 2022, European Respiratory Journal.

Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease

M. Kudo, Y. Minami, S. Hagiwara, 2021, Scientific Reports.

Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma

T. Yasuda, K. Nakagawa, K. Yonesaka, 2022, Esophagus.

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan

K. Imaizumi, M. Nishio, H. Kenmotsu, 2023, JTO clinical and research reports.

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

C. Chiu, Dong-Wan Kim, G. Chang, 2023, JTO clinical and research reports.

P1.01-103 Preliminary Results of Brigatinib in Japanese Patients (Pts) Who Previously Received Alectinib: Brigatinib-2001 Study

M. Satouchi, M. Nishio, T. Seto, 2019, Journal of Thoracic Oncology.

Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer

Toshio Shimizu, E. Kamiyama, K. Nakagawa, 2017, Cancer Chemotherapy and Pharmacology.

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705

K. Kiura, M. Tabata, M. Tanimoto, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC

P. Jänne, Melissa L. Johnson, M. Nishio, 2020 .

Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer

S. Olsen, H. Hayashi, Jiemin Liao, 2022, Current oncology.

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

Shinichiro Suzuki, Shigeki Shimizu, Kazuko Sakai, 2019, Scientific Reports.

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors

T. Mitsudomi, H. Handa, Kaoru Tanaka, 2020, The oncologist.

2169 Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinoma

K. Okuno, S. Tomida, K. Nishio, 2015 .

K. Nakagawa, H. Hayashi, K. Haratani, 2018, JAMA Oncology.

Incorrect Email Address for Corresponding Author.

K. Nakagawa, H. Hayashi, K. Haratani, 2018, JAMA Oncology.

A Randomized Phase II Study of a Combination of Docetaxel and S-1 versus Docetaxel Monotherapy in Patients with Non-small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy: Results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503

K. Matsuo, K. Kiura, M. Tabata, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in pts with NSCLC previously treated with platinum-based chemotherapy: Results of Okayama Lung Cancer Study Group (OLCSG) trial 0503.

K. Matsuo, K. Kiura, M. Tabata, 2009, Journal of Clinical Oncology.

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

K. Nishio, K. Nakagawa, K. Sakai, 2023, JTO clinical and research reports.

Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.

Kaoru Tanaka, Y. Hasegawa, K. Okamoto, 2016, Clinical lung cancer.

Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L).

Y. Koh, N. Yamamoto, S. Takamori, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

T. Mitsudomi, K. Azuma, I. Okamoto, 2020, Clinical lung cancer.

SO-8 Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR)

W. Ichikawa, H. Hayashi, M. Takahashi, 2022, Annals of Oncology.

Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.

K. Nishio, K. Azuma, N. Yamamoto, 2023, Clinical lung cancer.

Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.

Kaoru Tanaka, Y. Hasegawa, K. Okamoto, 2016, Clinical Lung Cancer.

Abstract. Patients with non-small cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements

K. Okuno, S. Tomida, K. Nishio, 2014 .

LBA55 WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expression

M. Oki, H. Saka, M. Satouchi, 2020 .

A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study

T. Yamanaka, H. Saka, Y. Nakanishi, 2019, Journal of Clinical Oncology.

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).

T. Yamanaka, H. Saka, Y. Nakanishi, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.

M. Satouchi, K. Azuma, K. Nakagawa, 2023, JAMA oncology.

T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer

J. Tanizaki, K. Nakagawa, K. Yonesaka, 2017, Molecular Cancer Therapeutics.

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Kaoru Tanaka, K. Nishio, I. Okamoto, 2012, Clinical Cancer Research.

AMPK activators suppress cholesterol accumulation in macrophages via suppression of the mTOR pathway.

H. Hayashi, Hiromasa Aoki, H. Kakita, 2023, Experimental cell research.

A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.

M. Oki, K. Azuma, Toshiaki Takahashi, 2023, Lung cancer.

Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy

M. Nishio, H. Hayashi, M. Kasahara-Kiritani, 2023, Advances in therapy.

Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations.

A. Shaw, J. Jassem, Sang-We Kim, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.

S. Tomida, M. D. De Velasco, K. Nishio, 2015, Lung cancer.

Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production

M. D. De Velasco, K. Nishio, H. Shiozaki, 2013, Oncotarget.

Keunchil Park, Y. Ichinose, E. Cho, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

K. Nishio, K. Nakagawa, H. Hayashi, 2014, Drug design, development and therapy.

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

H. Hayashi, Y. Togashi, Kazuhiko Nakagawa, 2014 .

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

H. Hayashi, Y. Togashi, Kazuhiko Nakagawa, 2014 .

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence